Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106262 · ClinicalTrials.gov registry record · Phase 2
Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer
A Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00106262 is a Phase 2 study that was terminated before completion, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 38 participants.
The verdict
NCT00106262, a Phase 2 study, was terminated before completion, sponsored by Women and Infants Hospital of Rhode Island.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study is conducting an evaluation of two chemotherapy drugs, Velcade and Irinotecan, in women with advanced, recurrent, or metastatic cervical cancer, vaginal cancer, or vulvar cancer. Patients with cervical cancer may have received a platinum-containing treatment as systemic therapy without radiation, but is not required.
Interventions
- DRUG Irinotecan
- DRUG Velcade (bortezomib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106262
The ClinicalTrials.gov registry entry for NCT00106262 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women and Infants Hospital of Rhode Island, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT00106262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106262 about?
NCT00106262 is a clinical study titled "Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer". This study is conducting an evaluation of two chemotherapy drugs, Velcade and Irinotecan, in women with advanced, recurrent, or metastatic cervical cancer, vaginal cancer, or vulvar cancer. Patients with cervical cancer may have received a platinum-containing treatment as systemic therapy without ra...
What is the current status of trial NCT00106262?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2005-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00106262?
The interventions under investigation include: Irinotecan (DRUG), Velcade (bortezomib) (DRUG).
Who is sponsoring clinical trial NCT00106262?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.